{"nctId":"NCT05633992","briefTitle":"Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)","startDateStruct":{"date":"2023-01-10","type":"ACTUAL"},"conditions":["Pneumococcal Disease"],"count":450,"armGroups":[{"label":"V116","type":"EXPERIMENTAL","interventionNames":["Biological: V116"]},{"label":"PPSV23","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: PPSV23"]}],"interventions":[{"name":"V116","otherNames":["Pneumococcal 21-valent Conjugate Vaccine"]},{"name":"PPSV23","otherNames":["PNEUMOVAX™23"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is Japanese\n* For females, is not pregnant or breastfeeding and is either not a participant of childbearing potential (POCBP) or is a POCBP and uses acceptable contraception/abstinence; has a negative highly sensitive pregnancy test (urine or serum) within 24 (urine) or 72 (serum) hours before the first dose of study intervention; and has medical, menstrual, and recent sexual activity history reviewed by the investigator to decrease the chance of inclusion of an early undetected pregnancy\n\nExclusion Criteria:\n\n* Has a history of invasive pneumococcal disease (IPD) \\[positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site\\] or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1)\n* Has a known hypersensitivity to any component of V116 or PPSV23, including diphtheria toxoid\n* Has a known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease\n* Has a coagulation disorder contraindicating IM vaccination\n* Had a recent febrile illness (defined as oral or tympanic temperature ≥100.4°F \\[≥38.0°C\\] or axillary or temporal temperature ≥99.4°F \\[≥37.4°C\\]) or received antibiotic therapy for any acute illness occurring \\<72 hours before receipt of study vaccine\n* Has a known malignancy that is progressing or has required active treatment \\<3 years before enrollment\n* Received prior pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside the protocol\n* Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention ≥14 days before receipt of study vaccine\n* Is currently receiving immunosuppressive therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease\n* Received any nonlive vaccine ≤14 days before receipt of study vaccine or is scheduled to receive any nonlive vaccine ≤30 days after receipt of study vaccine (inactivated influenza and SARS-CoV2 vaccines may be acceptable)\n* Received any live virus vaccine ≤30 days before receipt of study vaccine or is scheduled to receive any live virus vaccine ≤30 days after receipt of study vaccine\n* Received a blood transfusion or blood products, including immunoglobulin ≤6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product until the Day 30 postvaccination blood draw is complete","healthyVolunteers":true,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Solicited Injection-site Adverse Events (AEs)","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"39.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Solicited Systemic AEs","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The solicited systemic AEs were muscle pain/myalgia, headache, and tiredness/fatigue.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":null},{"groupId":"OG001","value":"16.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Vaccine-related Serious AEs (SAEs)","description":"An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs)","description":"The serotype-specific OPA GMTs for the 12 common serotypes contained in V116 and PPSV23, the unique serotype 15C in V116, and the cross-reactive serotype 15B were determined using the multiplex opsonophagocytic assay (MOPA).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"155.1","spread":null},{"groupId":"OG001","value":"170.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2675.1","spread":null},{"groupId":"OG001","value":"2411.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1293.3","spread":null},{"groupId":"OG001","value":"1142.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2844.8","spread":null},{"groupId":"OG001","value":"2710.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1591.2","spread":null},{"groupId":"OG001","value":"880.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1269.6","spread":null},{"groupId":"OG001","value":"887.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"968.5","spread":null},{"groupId":"OG001","value":"503.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3138.1","spread":null},{"groupId":"OG001","value":"1860.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1338.4","spread":null},{"groupId":"OG001","value":"1140.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2617.2","spread":null},{"groupId":"OG001","value":"1731.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1830.9","spread":null},{"groupId":"OG001","value":"1295.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7692.4","spread":null},{"groupId":"OG001","value":"8610.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2488.5","spread":null},{"groupId":"OG001","value":"1185.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2081.1","spread":null},{"groupId":"OG001","value":"1479.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":null},{"groupId":"OG001","value":"14.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"243.9","spread":null},{"groupId":"OG001","value":"217.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":null},{"groupId":"OG001","value":"46.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"383.1","spread":null},{"groupId":"OG001","value":"383.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131.5","spread":null},{"groupId":"OG001","value":"103.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.2","spread":null},{"groupId":"OG001","value":"91.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":null},{"groupId":"OG001","value":"19.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"285.8","spread":null},{"groupId":"OG001","value":"226.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188.1","spread":null},{"groupId":"OG001","value":"179.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"460.0","spread":null},{"groupId":"OG001","value":"421.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"179.9","spread":null},{"groupId":"OG001","value":"167.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1236.7","spread":null},{"groupId":"OG001","value":"1198.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110.0","spread":null},{"groupId":"OG001","value":"102.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"243.3","spread":null},{"groupId":"OG001","value":"251.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific OPAs (Unique to V116)","description":"The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPAs for the 8 unique serotypes contained in V116 (except for 15C) were determined.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.8","spread":null},{"groupId":"OG001","value":"45.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.7","spread":null},{"groupId":"OG001","value":"26.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.3","spread":null},{"groupId":"OG001","value":"11.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.6","spread":null},{"groupId":"OG001","value":"27.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.1","spread":null},{"groupId":"OG001","value":"43.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"16.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.3","spread":null},{"groupId":"OG001","value":"13.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Serotype-specific OPA GMTs (Unique Serotypes)","description":"The serotype-specific OPA GMTs for the 8 unique serotypes contained in V116 (except for serotype 15C) and the cross-reactive serotype 6C in V116 were determined using MOPA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1263.8","spread":null},{"groupId":"OG001","value":"641.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2752.3","spread":null},{"groupId":"OG001","value":"832.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4094.8","spread":null},{"groupId":"OG001","value":"1183.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2107.5","spread":null},{"groupId":"OG001","value":"729.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1359.0","spread":null},{"groupId":"OG001","value":"202.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2521.9","spread":null},{"groupId":"OG001","value":"1043.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2095.4","spread":null},{"groupId":"OG001","value":"260.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4758.1","spread":null},{"groupId":"OG001","value":"1051.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs)","description":"The GMCs for serotype-specific IgG antibodies were determined using pneumococcal electrochemiluminescence (PnECL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":null},{"groupId":"OG001","value":"0.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.12","spread":null},{"groupId":"OG001","value":"4.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.13","spread":null},{"groupId":"OG001","value":"6.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.49","spread":null},{"groupId":"OG001","value":"5.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.21","spread":null},{"groupId":"OG001","value":"3.84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.00","spread":null},{"groupId":"OG001","value":"3.02","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":null},{"groupId":"OG001","value":"0.66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.48","spread":null},{"groupId":"OG001","value":"5.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.70","spread":null},{"groupId":"OG001","value":"4.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.61","spread":null},{"groupId":"OG001","value":"9.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.84","spread":null},{"groupId":"OG001","value":"1.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.93","spread":null},{"groupId":"OG001","value":"12.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":null},{"groupId":"OG001","value":"1.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.98","spread":null},{"groupId":"OG001","value":"1.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.87","spread":null},{"groupId":"OG001","value":"4.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.07","spread":null},{"groupId":"OG001","value":"0.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":null},{"groupId":"OG001","value":"0.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.22","spread":null},{"groupId":"OG001","value":"1.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.79","spread":null},{"groupId":"OG001","value":"0.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.57","spread":null},{"groupId":"OG001","value":"0.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.19","spread":null},{"groupId":"OG001","value":"1.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":null},{"groupId":"OG001","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.15","spread":null},{"groupId":"OG001","value":"9.86","spread":null}]}]}]},{"type":"SECONDARY","title":"Serotype-specific Geometric Mean Fold Rise (GMFR) in OPA GMT","description":"The GMFR from baseline in serotype-specific OPA GMTs was determined using MOPA. GMFR is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":null},{"groupId":"OG001","value":"7.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"9.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"19.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":null},{"groupId":"OG001","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","spread":null},{"groupId":"OG001","value":"7.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.2","spread":null},{"groupId":"OG001","value":"17.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null},{"groupId":"OG001","value":"7.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":null},{"groupId":"OG001","value":"6.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":null},{"groupId":"OG001","value":"7.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":null},{"groupId":"OG001","value":"9.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":null},{"groupId":"OG001","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Serotype-specific GMFR in IgG GMCs","description":"The GMFR from baseline in GMCs for serotype-specific IgG antibodies was determined using PnECL. GMFR is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"5.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":null},{"groupId":"OG001","value":"9.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"9.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null},{"groupId":"OG001","value":"6.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"3.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":null},{"groupId":"OG001","value":"7.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null},{"groupId":"OG001","value":"6.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"6.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"7.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific OPA GMTs (All Serotypes)","description":"Activity for the serotypes contained in V116 and PPSV23 were determined using MOPA. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.8","spread":null},{"groupId":"OG001","value":"71.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":null},{"groupId":"OG001","value":"69.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.8","spread":null},{"groupId":"OG001","value":"81.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.6","spread":null},{"groupId":"OG001","value":"58.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.3","spread":null},{"groupId":"OG001","value":"59.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.3","spread":null},{"groupId":"OG001","value":"55.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.3","spread":null},{"groupId":"OG001","value":"74.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.1","spread":null},{"groupId":"OG001","value":"62.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.1","spread":null},{"groupId":"OG001","value":"61.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1","spread":null},{"groupId":"OG001","value":"42.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.0","spread":null},{"groupId":"OG001","value":"52.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.0","spread":null},{"groupId":"OG001","value":"63.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.8","spread":null},{"groupId":"OG001","value":"45.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.7","spread":null},{"groupId":"OG001","value":"26.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.0","spread":null},{"groupId":"OG001","value":"65.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.3","spread":null},{"groupId":"OG001","value":"11.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.6","spread":null},{"groupId":"OG001","value":"27.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.1","spread":null},{"groupId":"OG001","value":"43.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"16.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.3","spread":null},{"groupId":"OG001","value":"13.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.2","spread":null},{"groupId":"OG001","value":"25.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.2","spread":null},{"groupId":"OG001","value":"54.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific IgG GMCs (All Serotypes)","description":"Activity for the serotypes contained in V116 and PPSV23 were determined using PnECL. The percentage of participants who had ≥4-fold rise in IgG titers were calculated from baseline to postvaccination.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.4","spread":null},{"groupId":"OG001","value":"59.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"70.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":null},{"groupId":"OG001","value":"78.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","spread":null},{"groupId":"OG001","value":"75.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.1","spread":null},{"groupId":"OG001","value":"61.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.3","spread":null},{"groupId":"OG001","value":"44.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.3","spread":null},{"groupId":"OG001","value":"56.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.7","spread":null},{"groupId":"OG001","value":"69.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":null},{"groupId":"OG001","value":"47.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.1","spread":null},{"groupId":"OG001","value":"59.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.6","spread":null},{"groupId":"OG001","value":"56.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.6","spread":null},{"groupId":"OG001","value":"73.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.4","spread":null},{"groupId":"OG001","value":"45.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.9","spread":null},{"groupId":"OG001","value":"27.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"61.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","spread":null},{"groupId":"OG001","value":"8.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","spread":null},{"groupId":"OG001","value":"14.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","spread":null},{"groupId":"OG001","value":"35.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.6","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.6","spread":null},{"groupId":"OG001","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.0","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":null},{"groupId":"OG001","value":"6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.4","spread":null},{"groupId":"OG001","value":"65.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":225},"commonTop":["Injection site pain","Injection site erythema","Fatigue","Injection site swelling"]}}}